HK1211844A1 - Treatment of pulmonary disease - Google Patents

Treatment of pulmonary disease

Info

Publication number
HK1211844A1
HK1211844A1 HK15112720.5A HK15112720A HK1211844A1 HK 1211844 A1 HK1211844 A1 HK 1211844A1 HK 15112720 A HK15112720 A HK 15112720A HK 1211844 A1 HK1211844 A1 HK 1211844A1
Authority
HK
Hong Kong
Prior art keywords
treatment
pulmonary disease
pulmonary
disease
Prior art date
Application number
HK15112720.5A
Other languages
English (en)
Chinese (zh)
Inventor
‧普魯贊斯基
盧西亞諾‧阿多裡尼
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49753520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1211844(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of HK1211844A1 publication Critical patent/HK1211844A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15112720.5A 2012-11-28 2015-12-24 Treatment of pulmonary disease HK1211844A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730749P 2012-11-28 2012-11-28
PCT/US2013/072038 WO2014085474A1 (en) 2012-11-28 2013-11-26 Treatment of pulmonary disease

Publications (1)

Publication Number Publication Date
HK1211844A1 true HK1211844A1 (en) 2016-06-03

Family

ID=49753520

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112720.5A HK1211844A1 (en) 2012-11-28 2015-12-24 Treatment of pulmonary disease

Country Status (19)

Country Link
US (3) US20140148428A1 (xx)
EP (1) EP2925328A1 (xx)
JP (1) JP6270171B2 (xx)
KR (1) KR102106186B1 (xx)
CN (1) CN104853758A (xx)
AU (1) AU2013352288B2 (xx)
BR (1) BR112015012312A2 (xx)
CA (1) CA2891348C (xx)
CL (1) CL2015001442A1 (xx)
HK (1) HK1211844A1 (xx)
IL (1) IL239025B (xx)
MX (1) MX2015006710A (xx)
MY (1) MY170802A (xx)
NZ (1) NZ708501A (xx)
PH (1) PH12015501108A1 (xx)
RU (1) RU2693382C2 (xx)
SG (1) SG11201503697TA (xx)
TW (1) TWI636786B (xx)
WO (1) WO2014085474A1 (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102252561B1 (ko) 2013-11-22 2021-05-20 미나 테라퓨틱스 리미티드 Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
CN106459136B (zh) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 一种奥贝胆酸的制备方法
EA033603B1 (ru) * 2014-11-19 2019-11-08 Nzp Uk Ltd 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
CA2968301C (en) * 2014-11-19 2023-05-16 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
JP6700274B2 (ja) 2014-11-19 2020-05-27 エヌゼットピー ユーケー リミテッド ステロイドｆｘｒモジュレーター製造のための中間体としての６−アルキル−７−ヒドロキシ−４−エン−３−オンステロイド
TWI686401B (zh) * 2014-11-19 2020-03-01 英商Ｎｚｐ英國有限公司 化合物（三）
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CZ2015504A3 (cs) * 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
CN105085597B (zh) * 2015-08-28 2017-03-29 成都百裕制药股份有限公司 一种无定型奥贝胆酸的制备方法
KR20180052756A (ko) * 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
MA45761A (fr) * 2015-10-07 2021-04-21 Intercept Pharmaceuticals Inc Modulateurs du récepteur farnésoïde x
CN106589038A (zh) * 2015-10-15 2017-04-26 重庆医药工业研究院有限责任公司 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
CN106589039B (zh) * 2015-10-15 2019-12-17 苏州朗科生物技术股份有限公司 一种奥贝胆酸的制备方法及相关化合物
CN106668027A (zh) * 2015-11-05 2017-05-17 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸药物组合物及其制备方法
CN105399793A (zh) * 2015-12-24 2016-03-16 北京康立生医药技术开发有限公司 一种胆烷酸的制备方法
EP3414256B1 (en) 2016-02-10 2022-01-19 Dr. Reddy's Laboratories Limited Purification process involving amine salt of obeticholic acid
JPWO2017170858A1 (ja) * 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤
WO2017180577A1 (en) * 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
CN109415405A (zh) * 2016-06-01 2019-03-01 雷迪博士实验室有限公司 制备奥贝胆酸的方法
CN106046095B (zh) * 2016-06-06 2017-02-22 南京理工大学 奥贝胆酸的合成方法
MX2019003684A (es) * 2016-09-30 2019-08-05 Intercept Pharmaceuticals Inc Formas cristalinas de un derivado de acido biliar.
CN108117579A (zh) * 2016-11-29 2018-06-05 昆明积大制药股份有限公司 奥贝胆酸及其中间体的制备方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
EP3679138B1 (en) 2017-09-08 2023-03-22 MiNA Therapeutics Limited Hnf4a sarna compositions and methods of use
KR20190030805A (ko) * 2017-09-14 2019-03-25 경상대학교산학협력단 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
US11111265B2 (en) * 2017-11-02 2021-09-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing cholic acid compound
MA53388A (fr) 2018-07-25 2021-06-02 Novartis Ag Inhibiteurs d'inflammasome nlrp3
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
TW202122078A (zh) 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
CN113318114B (zh) * 2020-02-28 2023-02-17 广州市赛普特医药科技股份有限公司 小分子化合物在治疗肺上皮细胞损伤和/或血管内皮细胞损伤介导的疾病中的用途
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
TW202406550A (zh) 2022-08-03 2024-02-16 瑞士商諾華公司 Ｎｌｒｐ３炎性小體抑制劑

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
NO160330C (no) 1982-10-08 1989-04-12 Glaxo Group Ltd Anordning for aa administrere medikamenter til pasienter og medikamentpakning for anordningen.
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
NO166268C (no) 1985-07-30 1991-07-03 Glaxo Group Ltd Innretning for administrering av medikamenter til pasienter.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
CA2213442A1 (en) 1995-03-10 1996-09-19 The Minnesota Mining & Manufacturing Company Aerosol valves
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
CA2440680C (en) 2001-03-12 2010-06-01 Roberto Pellicciari Steroids as agonists for fxr
WO2005032549A1 (en) * 2003-09-26 2005-04-14 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
SI1734970T1 (sl) 2004-03-12 2015-04-30 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo FXR ligandov
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CN101522703B (zh) * 2006-06-27 2013-04-17 英特塞普特医药品公司 胆酸派生物及其在制备预防或治疗fxr介导的疾病或状况的药物中的应用
CA2655395C (en) * 2006-06-29 2011-10-11 F.Hoffmann-La Roche Ag Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same
BRPI0916735B8 (pt) * 2008-07-30 2021-05-25 Intercept Pharmaceuticals Inc compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos
CN106380502A (zh) * 2008-11-19 2017-02-08 英特塞普特医药品公司 G蛋白偶联受体5(tgr5)调节剂及其使用方法
WO2010069604A1 (en) * 2008-12-19 2010-06-24 Royal College Of Surgeons In Ireland Treatment of diarrhoea
EP2470553B1 (en) * 2009-08-25 2024-06-19 Qing Bile Therapeutics Inc. Polyhydroxylated bile acids for treatment of biliary disorders
US9416151B2 (en) * 2010-08-25 2016-08-16 Lurong ZHANG Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
KR101881245B1 (ko) * 2012-06-19 2018-07-23 인터셉트 파마슈티컬즈, 인크. 오베티콜산의 제조법, 용도 및 고체 형태

Also Published As

Publication number Publication date
KR102106186B1 (ko) 2020-05-04
CA2891348A1 (en) 2014-06-05
AU2013352288B2 (en) 2017-11-23
PH12015501108B1 (en) 2015-08-17
CA2891348C (en) 2020-04-28
MX2015006710A (es) 2016-01-15
KR20150089052A (ko) 2015-08-04
US20140148428A1 (en) 2014-05-29
AU2013352288A1 (en) 2015-06-04
CL2015001442A1 (es) 2015-08-28
US20180064729A1 (en) 2018-03-08
JP2016500111A (ja) 2016-01-07
RU2015122027A (ru) 2017-01-10
NZ708501A (en) 2019-03-29
BR112015012312A2 (pt) 2017-07-11
MY170802A (en) 2019-08-28
SG11201503697TA (en) 2015-06-29
US20160213689A1 (en) 2016-07-28
TWI636786B (zh) 2018-10-01
EP2925328A1 (en) 2015-10-07
PH12015501108A1 (en) 2015-08-17
CN104853758A (zh) 2015-08-19
TW201434469A (zh) 2014-09-16
IL239025A0 (en) 2015-07-30
RU2693382C2 (ru) 2019-07-02
IL239025B (en) 2021-04-29
JP6270171B2 (ja) 2018-01-31
WO2014085474A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
HK1211844A1 (en) Treatment of pulmonary disease
HK1201452A1 (en) Methods of reducing risk of cardiovascular disease
EP2890418A4 (en) VENTRICULAR CUFF
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
HK1200348A1 (en) Methods and materials for treatment of pompes disease
ZA201406082B (en) Use of ccr3-inhibitors
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
EP2704723A4 (en) TREATMENT OF POLYCYSTIC DISEASES
IL234606B (en) Innovative methods and compounds for the treatment of diseases
HK1211213A1 (en) Treatment of diseases involving mucin
EP2900259A4 (en) GLYCOSIDASE DOSAGE PLAN FOR THE TREATMENT OF INFECTION DISEASES
ZA201501038B (en) Treatment of wax
GB201312378D0 (en) Structure of shoe
GB201207907D0 (en) Treatment of depression
GB201204645D0 (en) Treatment of disease
GB201219092D0 (en) Treatment of cardiovascular disease
GB201201778D0 (en) Treatment of inflammatory respiratory disease
EP2911662A4 (en) METHOD OF TREATING A DISEASE
GB201320014D0 (en) Treatment of cardiovascular disease
GB201321628D0 (en) Treatment of disease
GB201118269D0 (en) Treatment of cardiovascular disease
GB201107988D0 (en) Treatment of cardiovascular disease
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment